Zobrazeno 1 - 10
of 255
pro vyhledávání: '"bcr-abl mutations"'
Autor:
Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusion of BCR and ABL genes and characterized by the presence of the reciprocal translocation t(9;22)(q34;q11). BCR-ABL, a product of the BCR-ABL fusion ge
Externí odkaz:
https://doaj.org/article/b8bba039315d4a539a22ded533e47c22
Autor:
Liuya Wei, Yang Yang, Pranav Gupta, Aihong Wang, Min Zhao, Yao Zhao, Mei Qu, Yu Ke, Ying Liu, Hong-Min Liu, Xin Xu, Yanli Sun, Zhe-Sheng Chen, Zhenbo Hu
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss , Pp 137-148 (2020)
Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph+) chromosome carrying the BCR-ABL oncogene, a constitutively active tyrosine kinase. The discovery of imatinib represents a major success story in the treatment against CML. However, mu
Externí odkaz:
https://doaj.org/article/c93fc53834974461a6c081f1cf87123a
Autor:
Zafar Iqbal, Tanveer Akhtar, Ahmad M Khalid, Aamer Aleem, Amer Mahmood, Afia M Akram, Mahmood Rasool, Ijaz H Shah, Aysha Bhalli, Muhammad Khalid, Mudassar Iqbal, Abid Jameel, Nawaf Al-Anazi
Publikováno v:
Journal of Applied Hematology, Vol 11, Iss 3, Pp 108-111 (2020)
BACKGROUND: Although tyrosine kinase inhibitors (TKIs) are the gold standard in clinical management of chronic myeloid leukemia, it is not feasible to use these drugs in at least some cases when patients are resistance to all available TKIs due to co
Externí odkaz:
https://doaj.org/article/654a09f59bfc42699192cf8c0c5b3300
Autor:
Radowan Elnair, Ahmed Galal
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
Abstract Background Chronic myeloid leukemia can be effectively treated with BCR-ABL1 tyrosine kinase inhibitors. However, BCR-ABL1 mutations can develop and cause secondary resistance to these inhibitors. For each of the available BCR-ABL1 inhibitor
Externí odkaz:
https://doaj.org/article/21eab6b1b36a47f585277bb1090a7193
Autor:
Giuseppe Pietrantuono
Publikováno v:
Clinical Management Issues, Vol 7, Iss 1S, Pp 13-17 (2015)
We reported a case report of a female patient with chronic myeloid leukemia who was treated with nilotinib after failure to imatinib, nilotinib, dasatinib. The patient was diagnosed in 2001 and treated with imatinib, but complete cytogenetic response
Externí odkaz:
https://doaj.org/article/836a71af8f234476995466d7d48fd55b
Autor:
Altınok Güneş, Buket, Hekmatshoar, Yalda, Özkan, Tülin, Bozkurt, Süreyya, Erdoğan Aydos, O. Sena, Büyükaşık, Yahya, Aladağ, Elifcan, Sunguroğlu, Asuman
Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusion of BCR and ABL genes and characterized by the presence of the reciprocal translocation t(9;22)(q34;q11). BCR-ABL, a product of the BCR-ABL fusion ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10176::14def80a66cd29fdd833e99a085ad565
https://hdl.handle.net/20.500.12939/3196
https://hdl.handle.net/20.500.12939/3196
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ferdinando Porretto
Publikováno v:
Clinical Management Issues, Vol 5, Iss 6S, Pp 11-16 (2015)
We report a case of a patient with chronic myeloid leukemia in chronic phase who was treated with Imatinib as first line therapy. He showed a suboptimal response by 2006 ELN criteria after six months, for this reason we performed a mutational analysi
Externí odkaz:
https://doaj.org/article/a4a2b4ecfde944069d7b3fbab56a8dca
Autor:
Luigia Luciano
Publikováno v:
Clinical Management Issues, Vol 4, Iss 5S, Pp 15-18 (2015)
Imatinib, a BCR-ABL inhibitor, is the standard of care for the first-line treatment of patients with chronic-phase CML. Despite the optimal results, some patients develop resistance to imatinib. For these patients, the second-generation tyrosine kina
Externí odkaz:
https://doaj.org/article/e117002a6a524dc182c57882b243e40c
Autor:
E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan
Publikováno v:
Онкогематология, Vol 7, Iss 4, Pp 16-23 (2014)
Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 %
Externí odkaz:
https://doaj.org/article/8a53efc214024456b8e2250dca14433f